Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 6, 2015
Event Date: April 3, 2015
Context: The Company entered into a material definitive agreement to lease new corporate headquarters and laboratory space in Cambridge, Massachusetts.
Key Financial Metrics and Obligations
This filing reports on a specific contractual obligation rather than periodic financial performance. Key financial terms of the new lease include:
- Annual Rent (Year 1): $19.8 million (exclusive of operating expenses and real property taxes).
- Rent Escalation: 3% annual increase thereafter.
- Landlord Contribution: $56.1 million toward base building and tenant improvements.
- Lease Term: 15 years from the rent commencement date, with options to renew for two additional five-year terms.
- Space Size: Approximately 295,000 square feet.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, or total debt.
Material Changes and Operational Impact
New Headquarters: The Company intends to move its corporate headquarters to the new premises at 675 West Kendall Street in early 2019.
Current Headquarters: The Company continues to lease approximately 129,000 square feet at 300 Third Street, Cambridge, under a non-cancelable lease through September 2021 (with a five-year renewal option).
Right of First Offer: The Company has a one-time right of first offer for all rentable space at 500 Kendall Street, provided the Company occupies 70% or more of the new premises and at least ten years remain on the lease term.
Guidance, Risks, and Contingencies
Timeline: The lease term commences May 1, 2018. Rent payments are expected to begin around February 1, 2019, upon substantial completion of building improvements.
Risks and Termination: The Landlord may terminate the lease if the Company fails to remedy a breach within specified time periods, or upon the Company's bankruptcy or insolvency.
Management Commentary: The filing contains no forward-looking guidance regarding financial performance or product development, focusing solely on the real estate transaction.
Key Facts for Investor Verification
- Verify the impact of the $19.8 million annual rent obligation on future operating expenses and cash flow projections.
- Confirm the status of the $56.1 million landlord contribution and its accounting treatment (e.g., capitalization vs. expense reduction).
- Monitor the timeline for the move to the new headquarters in early 2019 and the associated transition costs.
- Review the remaining obligations on the current 300 Third Street lease through September 2021 to assess total real estate exposure.